Is Thermo Fisher Scientific (TMO) overvalued or fairly valued?

MarketChacha shows Thermo Fisher Scientific's valuation in context — a trailing P/E of about 39.1, a forward P/E of about 25.0, a price-to-book of about 4.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Thermo Fisher Scientific's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.31×) from reported figures — education, not a rating.

What is Thermo Fisher Scientific's revenue?

Thermo Fisher Scientific reported revenue of $44.6B for FY2025, with net profit of $6.7B, per official filings.

What is the share price of Thermo Fisher Scientific (TMO)?

Thermo Fisher Scientific last traded at $690.00 (-0.9% on the day), as of 10/16/2026 — a delayed quote shown for education, not investment advice.

Thermo Fisher Scientific

TMO · NYSE · Life Sciences · United States

Snapshot

TickerTMO

ExchangeNYSE

SectorLife Sciences

IndustryDiagnostics & Research

CountryUnited States

Employees125,000

HeadquartersWaltham, United States

Websitewww.thermofisher.com

Filings tracked17

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Who owns it

Insiders0.1%
Institutions94.0%
Public & other5.9%

3,582 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.36%
Vanguard Capital Management LLC6.57%
State Street Corporation4.55%
FMR, LLC3.81%
Morgan Stanley2.91%
JPMORGAN CHASE & CO2.30%
Geode Capital Management, LLC2.27%
Franklin Resources, Inc.1.97%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.31×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend14.0% → 15.0%

Margin has expanded by about 1.1 points — the business is getting more profitable.

Growth qualityrev 2% · PAT 6%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $12.9B · EPS 7.28

Est. earnings growth +10.7%

Next fiscal year

Rev $50.4B · EPS 27.58

Est. earnings growth +9.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$44.6B

Net margin

15.0%

ROE

12.6%

Revenue CAGR (2y)

+2.0%

Profit CAGR (2y)

+5.7%

EPS (FY2025)

17.74

Net profit (FY2025)

$6.7B

Ask MarketChacha about TMO

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

On MarketChacha

Posts about TMO

HCL Technologies: what their latest filing actually meansc/india-daily · 9/8/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$44.6B	$6.7B	17.74	15.0%	12.6%
FY2024	$42.9B	$6.3B	16.53	14.8%	12.8%
FY2023	$42.9B	$6.0B	15.45	14.0%	12.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$12.0B	$1.7B	4.68	14.5%
2026Q1	$11.0B	$1.7B	4.43	15.0%
2025Q3	$11.1B	$1.6B	4.27	14.5%
2025Q2	$10.9B	$1.6B	4.28	14.9%
2025Q1	$10.4B	$1.5B	3.98	14.5%
2024Q3	$10.6B	$1.6B	4.25	15.4%
2024Q2	$10.5B	$1.5B	4.04	14.7%
2024Q1	$10.3B	$1.3B	3.46	12.9%
2023Q3	$10.6B	$1.7B	4.42	16.0%
2023Q2	$10.7B	$1.3B	3.32	12.1%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/31/2026
8-K — Results of operations, Exhibits
SEC7/23/2026material
8-K — Shareholder vote results
SEC5/26/2026material
10-Q filing
SEC5/1/2026
8-K — Results of operations, Exhibits
SEC4/23/2026material
8-K — Other events, Exhibits
SEC3/24/2026material
10-K filing
SEC2/26/2026
8-K — Material agreement, Other events, Exhibits
SEC2/12/2026material
8-K — Results of operations, Exhibits
SEC1/29/2026material
8-K — Executive/director change
SEC1/12/2026material

2025

8-K — Material agreement, Other events, Exhibits
SEC12/1/2025material
10-Q filing
SEC10/31/2025
8-K — Other events, Exhibits
SEC10/29/2025material
8-K — Results of operations, Exhibits
SEC10/22/2025material
8-K — Material agreement, Other events, Exhibits
SEC10/7/2025material
8-K — Other events, Exhibits
SEC9/2/2025material
10-Q filing
SEC8/1/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.